Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, In-situ Hybridization, Microarray)- Forecast to 2021

  • ID: 3985688
  • Report
  • 156 Pages
  • Markets and Markets
1 of 5
Global Cancer/Tumor Profiling Market is Projected to Reach USD 8.74 Billion in 2022 from USD 5.26 Billion in 2017 at CAGR of 10.7%.

FEATURED COMPANIES

  • Caris Life Sciences
  • Genomic Health Inc.
  • Helomics Corporation
  • Illumina, Inc.
  • Oxford Gene Technology
  • Qiagen N.V.
  • MORE

“The global cancer/tumor profiling market is projected to grow at a CAGR of 10.7%.”

The cancer/tumor profiling market is primarily driven by the increasing number of cancer cases, growing utility of biomarkers in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer/tumor profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market.

“The immunoassays segment is expected to account for the largest share in 2017.”

On the basis of technology, the global cancer/tumor profiling market is broadly divided into immunoassays, hybridization, NGS, mass spectrometry, and other technologies. In 2017, the immunoassays segment is expected to account for the largest share of the cancer/tumor profiling technologies market. The high sensitivity and cost-effectiveness of these techniques as well as technological advancements in these immunoassays tests are factors that are expected to propel the growth of this market in the coming years. Furthermore, the hybridization technology is again divided on the basis of type which includes PCR, in-situ hybridization, and microarrays. The PCR segment is expected to account for the largest market share of hybridization technology in 2017. PCR is one of the most widely used technologies in the diagnostics market. This is primarily due to its ease of use, cost-effectiveness, quick turnaround time (4 to 6 hours), and easy availability of kits and reagents.

“The clinical application segment is expected to account for the largest share in 2017.”

Based on application, the cancer/tumor profiling market is categorized into clinical application, and research application. In 2017, the clinical application segment is expected to account for the largest share of the cancer/tumor profiling market. Technological advancements and the need for early diagnosis are further aiding market growth in this segment.

“North America is expected to account for the largest share in 2017.”

Among the four regions, North America is expected to account for the largest share of the cancer/tumor profiling market in 2017, followed by Europe, APAC, and the RoW. The large share of the North American market is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region.

Break-up profile of primaries:

  • By Company Type- Tier 1-45%, Tier 2-34% and Tier 3-21%
  • By Designation- C-level-14%, D-level-10% and Others-76%
  • By Region- North America-40%, Europe-32%, Asia Pacific-20%, and RoW-8%

The cancer/tumor profiling market is dominated by established players such as Illumina (US), QIAGEN (Netherlands), NeoGenomics Laboratories (US), HTG Molecular Diagnostic (US), and Genomic Health (US).

Research Coverage:

The cancer/tumor profiling market in this report is segmented by cancer type, application, technology, and region. The study tracks and analyzes competitive developments such as product launches, collaborations, agreements, partnerships, and acquisitions, and profiles key players and core competencies in the cancer/tumor profiling market.

Reasons to buy this report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes the market by function, solution, end user, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global cancer/tumor profiling market
  • Market Development: Comprehensive information about lucrative emerging markets - the report analyzes the markets for global cancer/tumor profiling products across regions
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global cancer/tumor profiling market
  • Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global cancer/tumor profiling market
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Caris Life Sciences
  • Genomic Health Inc.
  • Helomics Corporation
  • Illumina, Inc.
  • Oxford Gene Technology
  • Qiagen N.V.
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.3 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Market Size Estimation
2.2 Market Breakdown And Data Triangulation
2.2.1 Key Data from Secondary Sources
2.2.2 Key Data from Primary Sources
2.2.2.1 Key Industry Insights
2.2.3 Assumptions for the Study
2.3 Macroeconomic Factor Analysis
2.3.1 Introduction
2.3.2 Demand-Side Analysis
2.3.2.1 Healthcare Expenditure Pattern
2.3.3 Supply-Side Analysis
2.3.3.1 Number of New Product Launches

3 Executive Summary

4 Premium Insights
4.1 Cancer/Tumor Profiling: Market Overview
4.2 Geographic Analysis: Cancer/Tumor Profiling Market, By Technology (2017)
4.3 Cancer/Tumor Profiling Market, By Application
4.4 Cancer/Tumor Profiling Market, By Hybridization Technology
4.5 Geographical Snapshot of the Cancer/Tumor Profiling Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Number of New Cancer Cases
5.2.1.2 Increasing Utility of Biomarkers in Tumor Profiling
5.2.1.3 Availability of Funding for Cancer Research
5.2.2 Restraints
5.2.2.1 High Capital Investments And Low Benefit Ratio for Biomarkers
5.2.2.2 Lack of Skilled Professionals And Infrastructure
5.2.3 Opportunities
5.2.3.1 Point-Of-Care Diagnostic Tests
5.2.3.2 Increasing Demand for Personalized Medicine
5.2.4 Challenge
5.2.4.1 Unclear Regulatory And Reimbursement Scenario

6 Cancer/Tumor Profiling Market, By Technology
6.1 Introduction
6.2 Immunoassays
6.3 Hybridization
6.3.1 Pcr
6.3.2 in Situ Hybridization (Ish)
6.3.3 Dna/Rna Microarray
6.4 Next Generation Sequencing
6.5 Mass Spectrometry
6.6 Other Technologies

7 Cancer/Tumor Profiling Market, By Cancer Type
7.1 Introduction
7.2 Breast Cancer
7.3 Lung Cancer
7.4 Colorectal Cancer
7.5 Prostate Cancer
7.6 Melanoma Cancer
7.7 Others Cancer

8 Cancer/Tumor Profiling Market, By Application
8.1 Introduction
8.2 Clinical Application
8.3 Research Application

9 Cancer/Tumor Profiling Market, By Region
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.4 Asia-Pacific
9.5 Rest of the World (Row)

10 Competitive Landscape
10.1 Overview
10.2 Battle for Market Share: Product Launch Was the Key Growth Strategy Adopted By Market Players Between 2013 And 2016
10.3 Product Launches
10.4 Agreements, Collaborations, And Partnerships
10.5 Acquisitions
10.6 Others Strategies

11 Company Profiles
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, Mnm View)*
11.1 Introduction
11.2 Illumina, Inc.
11.3 Qiagen N.V.
11.4 Neogenomics Laboratories, Inc.
11.5 Htg Molecular Diagnostics, Inc.
11.6 Genomic Health Inc.
11.7 Caris Life Sciences
11.8 Helomics Corporation
11.9 Nanostring Technologies, Inc.
11.10 Oxford Gene Technology
11.11 Ribomed Biotechnologies, Inc.
*Details On View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

12 Appendix
12.1 Insights of Industry Experts
12.2 Discussion Guide
12.3 Other Developments
12.4 Knowledge Store: Subscription Portal
12.5 Introducing Rt: Real-Time Market Intelligence
12.6 Available Customizations
12.7 Related Reports
12.8 Author Details

List of Tables
Table 1 List of Fda-Approved Biomarkers for Different Types of Cancer
Table 2 National Institutes of Health (Nih) Spending, By Type of Cancer (Financial Year 2015)
Table 3 Cancer/Tumor Profiling Market Size, By Technology, 2015-2022 (USD Million)
Table 4 Hybridization Market for Cancer/Tumor Profiling, By Technology, 2015-2022 (USD Million)
Table 5 Global Immunoassays Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 6 North America: Immunoassays Market for Cancer/Tumor Profiling, By Country, 2015-2022 (USD Million)
Table 7 Global Hybridization Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 8 North America: Hybridization Market for Cancer/Tumor Profiling, By Country, 2015-2022 (USD Million)
Table 9 Global Pcr Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 10 North America: Pcr Market for Cancer/Tumor Profiling, By Country, 2015-2022 (USD Million)
Table 11 Global in Situ Hybridization Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 12 North America: in Situ Hybridization Market for Cancer/Tumor Profiling, By Country, 2015-2022 (USD Million)
Table 13 Global Dna/Rna Microarray Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 14 North America: Dna/Rna Microarray Market for Cancer/Tumor Profiling, By Country, 2015-2022 (USD Million)
Table 15 Global Next-Generation Sequencing Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 16 North America: Next-Generation Sequencing Market for Cancer/Tumor Profiling, By Country, 2015-2022 (USD Million)
Table 17 Global Mass Spectrometry Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 18 North America: Mass Spectrometry Market for Cancer/Tumor Profiling, By Country, 2015-2022 (USD Million)
Table 19 Global Other Technologies Market for Cancer/Tumor Profiling, By Region, 2015-2022 (USD Million)
Table 20 North America: Other Technologies Market for Cancer/Tumor Profiling, By Country, 2015-2022 (USD Million)
Table 21 Global Cancer/Tumor Profiling Market Size, By Cancer Type, 2015-2022 (USD Million)
Table 22 Global Breast Cancer/Tumor Profiling Market Size, By Region, 2015-2022 (USD Million)
Table 23 North America Breast Cancer/Tumor Profiling Market, By Country, 2015-2022 (USD Million)
Table 24 Global Lung Cancer/Tumor Profiling Market, By Region, 2015-2022 (USD Million)
Table 25 North America Lung Cancer/Tumor Profiling Market, By Country, 2015-2022 (USD Million)
Table 26 Global Colorectal Cancer/Tumor Profiling Market, By Region, 2015-2022 (USD Million)
Table 27 North America Colorectal Cancer/Tumor Profiling Market, By Country, 2015-2022 (USD Million)
Table 28 Global Prostate Cancer/Tumor Profiling Market, By Region, 2015-2022 (USD Million)
Table 29 Global Melanom Cancer/Tumor Profiling Market, By Region, 2015-2022 (USD Million)
Table 30 North America Melanoma Cancer/Tumor Profiling Market, By Country, 2015-2022 (USD Million)
Table 31 Global Other Type of Cancer/Tumor Profiling Market, By Region, 2015-2022 (USD Million)
Table 32 North America Other Type of Cancer/Tumor Profiling Market By Country, 2015-2022 (USD Million)
Table 33 Cancer/Tumor Profiling Market Size, By Application, 2015-2022 (USD Million)
Table 34 Cancer/Tumor Profiling Market for Clinical Application, By Region, 2015-2022 (USD Million)
Table 35 North America: Cancer/Tumor Profiling Market for Clinical Application, By Region, 2015-2022 (USD Million)
Table 36 Cancer/Tumor Profiling Market for Resaerch Application, By Region, 2015-2022 (USD Million)
Table 37 North America: Cancer/Tumor Profiling Market for Resaerch Application, By Region, 2015-2022 (USD Million)
Table 38 Global Cancer/Tumor Profiling Market, By Region, 2015-2022 (USD Million)
Table 39 North America: Cancer/Tumor Profiling Market Size, By Country, 2015-2022 (USD Million)
Table 40 North America: Cancer/Tumor Profiling Market Size, By Cancer Type, 2015-2022 (USD Million)
Table 41 North America: Cancer/Tumor Profiling Market, By Technology, 2015-2022 (USD Million)
Table 42 North America: Hybridization Technology Market, By Type, 2015-2022 (USD Million)
Table 43 North America: Cancer/Tumor Profiling Market, By Application, 2015-2022 (USD Million)
Table 44 Us: Cancer/Tumor Profiling Market, By Technology, 2015-2022 (USD Million)
Table 45 Us: Hybridization Technology Market, By Type, 2015-2022 (USD Million)
Table 46 Us: Cancer/Tumor Profiling Market, By Application, 2015-2022 (USD Million)
Table 47 Us: Cancer/Tumor Profiling Market, By Cancer Type, 2015-2022 (USD Million)
Table 48 Canada: Cancer/Tumor Profiling Market, By Technology, 2015-2022 (USD Million)
Table 49 Canada: Hybridization Technology Market, By Type, 2015-2022 (USD Million)
Table 50 Canada: Cancer/Tumor Profiling Market, By Application, 2015-2022 (USD Million)
Table 51 Canada: Cancer/Tumor Profiling Market, By Cancer Type, 2015-2022 (USD Million)
Table 52 Europe: Cancer/Tumor Profiling Market, By Cancer Type, 2015-2022 (USD Million)
Table 53 Europe: Cancer/Tumor Profiling Market, By Technology, 2015-2022 (USD Million)
Table 54 Europe: Hybridization Technology Market, By Type, 2015-2022 (USD Million)
Table 55 Europe: Cancer/Tumor Profiling Market, By Application, 2015-2022 (USD Million)
Table 56 Asia-Pacific: Cancer/Tumor Profiling Market, By Cancer Type, 2015-2022 (USD Million)
Table 57 Asia-Pacific: Cancer/Tumor Profiling Market, By Technology, 2015-2022 (USD Million)
Table 58 Asia-Pacific: Hybridization Technology Market, By Type, 2015-2022 (USD Million)
Table 59 Asia-Pacific: Cancer/Tumor Profiling Market, By Application, 2015-2022 (USD Million)
Table 60 Row: Cancer/Tumor Profiling Market, By Cancer Type, 2015-2022 (USD Million)
Table 61 Row: Cancer/Tumor Profiling Market, By Technology, 2015-2022 (USD Million)
Table 62 Row: Hybridization Technology Market, By Type, 2015-2022 (USD Million)
Table 63 Row: Cancer/Tumor Profiling Market, By Application, 2015-2022 (USD Million)
Table 64 Product Launches, 2013-2016
Table 65 Agreements, Collaborations, And Partnerships, 2013-2016
Table 66 Acquisitions, 2013-2016
Table 67 Other Strategies, 2013-2016

List of Figures
Figure 1 Research Design
Figure 2 Cancer/Tumor Profiling Market Top Down Approach
Figure 3 Cancer/Tumor Profiling Market: Bottom Up Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, And Region
Figure 5 Market Data Triangulation Methodology
Figure 6 Healthcare Expenditure Across Major Countries: 2000 Vs. 2014
Figure 7 Cancer/Tumor Profiling Market, By Cancer Type, 2017 Vs. 2022 (USD Million)
Figure 8 Cancer/Tumor Profiling Market, By Technology, 2017 Vs. 2022 (USD Million)
Figure 9 Cancer/Tumor Profiling Market, By Hybridization Technology, 2017 Vs. 2022 (USD Million)
Figure 10 Cancer/Tumor Profiling Market, By Application, 2017 Vs. 2022 (USD Million)
Figure 11 Geographical Snapshot of the Cancer/Tumor Profiling Market
Figure 12 Technology Advancement is a Major Driver for the Cancer/Tumor Profiling Market Growth in 2017
Figure 13 Clinical Application Will Continue to Dominate the Cancer/Tumor Profiling Market in 2022
Figure 14 Pcr is Expected to Be the Fastest Growing Segment During Forecast Period
Figure 15 Apac Will Be the Fastest-Growing Market from 2017 to 2022
Figure 16 Cancer/Tumor Profiling Market: Drivers, Restraints, Opportunities, And Challenges
Figure 17 Increasing Number of New Cancer Cases Worldwide (2012 Vs. 2015 Vs. 2020)
Figure 18 New Cancer Cases, By Country (2012)
Figure 19 New Cancer Cases, By Country (2020)
Figure 20 Immunoassays Segment to Dominate the Market in the Forecast Period
Figure 21 Clinical Application Segment to Dominate the Market in the Forecast Period
Figure 22 Cancer/Tumor Profiling Market: Geographic Snapshot (2017-2022)
Figure 23 North America Market Snapshot
Figure 24 Asia-Pacific Cancer/Tumor Profiling Market Snapshot
Figure 25 Companies Majorly Pursued the Strategy of Product Launch Between 2013 And 2016
Figure 26 Geographic Revenue Mix of the Prominent Players in the Cancer/Tumor Profiling Market
Figure 27 Company Snapshot: Illumina, Inc.
Figure 28 Company Snapshot: Qiagen N.V.
Figure 29 Company Snapshot: Neogenomics Laboratories, Inc.
Figure 30 Company Snapshot: Htg Molecular Diagnostics, Inc.
Figure 31 Company Snapshot: Genomic Health Inc.
Figure 32 Company Snapshot: Nanostring Technologies, Inc.

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Caris Life Sciences
  • Genomic Health Inc.
  • Helomics Corporation
  • Illumina, Inc.
  • Oxford Gene Technology
  • Qiagen N.V.
  • MORE

Global cancer profiling market is projected to reach USD 8.74 Billion in 2022 from USD 5.26 Billion in 2017 at CAGR of 10.7%. Growth in the cancer/tumor profiling market is driven by the increasing number of cancer cases, growing utility of biomarker in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer/tumor profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market.

In this report, the global cancer profiling market in this report is segmented by cancer type, application, technology, and region. On the basis of cancer type, the cancer type market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other cancer types. In 2017, the breast cancer segment is expected to account for the largest share of the global cancer/tumor profiling market. The largest share of this segment is mainly attributed to the high prevalence of breast cancer over the last few years, increased awareness about breast cancer diagnosis, and increasing research focus on breast cancer.

On the basis of technology, the global cancer profiling market is broadly divided into immunoassays, hybridization, NGS, mass spectrometry, and other technologies. In 2017, the immunoassays segment is expected to account for the largest share of the cancer/tumor profiling technologies market. The high sensitivity and cost-effectiveness of these techniques as well as technological advancements in these immunoassays tests are factors that are expected to propel the growth of this market in the coming years. Furthermore, the hybridization technology is again divided on the basis of type which includes PCR, in-situ hybridization, and microarrays. The PCR segment is expected to account for the largest market share of hybridization technology in 2017. PCR is one of the most widely used technologies in the diagnostics market. This is primarily due to its ease of use, cost-effectiveness, quick turnaround time (4 to 6 hours), and easy availability of kits and reagents.

North America is expected to account for the largest share of the cancer/tumor profiling market in 2017. Asia Pacific is estimated to witness the highest growth during the forecast period. The Asia Pacific region is expected to register the highest CAGR in the forecast period. In recent years, the Asia Pacific market for cancer/tumor profiling has witnessed significant growth due to the rising incidence of cancer, increasing demand for better healthcare services in developing economies such as India and China, rising number of contract research organizations (CROs), and increasing focus of international players on emerging markets.

Major players operating in the cancer profiling market include Illumina (US), QIAGEN (Netherlands), NeoGenomics Laboratories (US), HTG Molecular Diagnostic (US), and Genomic Health (US). These players focus on inorganic strategies such as acquisitions, agreements, and collaborations as well as organic strategies such as product launches and expansions to sustain their growth in the cancer/tumor profiling market.

Note: Product cover images may vary from those shown
5 of 5
  • Caris Life Sciences
  • Genomic Health Inc.
  • Helomics Corporation
  • Htg Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • Neogenomics Laboratories, Inc.
  • Oxford Gene Technology
  • Qiagen N.V.
  • Ribomed Biotechnologies, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll